247wallst.com · 10 jul

Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up

Shares of Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) are down 9% intraday, changing hands near $58.30 after opening the session at $64.27.

benzinga.com · 10 jul

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) said on Thursday that their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.

prnewswire.com · 10 jul

IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals

/PRNewswire/ -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) dropped more than 20% pre-market on July 9, 2026, after the Company announced that its

prnewswire.com · 9 jul

Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating.

seekingalpha.com · 9 jul

AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic

AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and in line for royalties on sales of eplontersen, also fell by >20%. AZN's ambitious $80bn 2030 revenue target now faces a ~$15bn gap by my calculation, but a robust late-stage pipeline and strong oncology division provide resilience.

benzinga.com · 9 jul

Ionis, AstraZeneca Pivotal Heart Disease Drug Flunks

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) on Thursday said their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.

barrons.com · 9 jul

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.

reuters.com · 9 jul

AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial

AstraZeneca said ​on Thursday ‌that its drug ​Wainua, ​made in partnership ⁠with ​Ionis , ​failed to meet the ​main ​goal of reducing ‌cardiovascular ⁠deaths and recurring heart ​problems ​in ⁠a late-stage ​trial.